ABOUT HEMGENIX

Range of suitable patients: CDEC discussed the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who're classified as getting moderate or average ailment could have a serious bleeding phenotyp